AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
choline fenofibrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| clofibrate derivatives, peroxisome proliferator activated receptor-alpha(PPAR-alpha) agonists | 4505 | 42017-89-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
metabolite of lipantyl; structure; salt of cholesterylamine & 2-(4-(p-chlorobenzoyl)phenoxy)2-methylpropionic acid
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.14 | g | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 0.114 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.089 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 82.414 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 4.188 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 1.030 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 1.870 | % | High | 1 |
| herg | hERG pIC50 | 4.357 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 4.550 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.162 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.800 | % | High | 1 |
| kinase-safety-class | ACVR2B,AURKA,AXL,BRAF,BTK,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,IKBKB,MAP2K6,MAPK7,MAPKAPK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TEK,TGFBR1 | 22 | |||
| kinase-selectivity-class | ACVR2B,EIF2AK3,GRK2,MAP2K6,PDK4 | 5 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 4.955 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 12.764 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 4.150 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.585 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | Moderate | 0.68 | |
| pppb | Pig plasma protein binding (% unbound) | 1.270 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 5.943 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 80.720 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 0.890 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 903.649 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 15, 2008 | FDA | ABBVIE |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pancreatitis | 24.25 | 23.93 | 15 | 1394 | 93518 | 110494372 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C10AB11 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Fibrates |
| MeSH PA | D000924 | Anticholesteremic Agents |
| MeSH PA | D000960 | Hypolipidemic Agents |
| MeSH PA | D000963 | Antimetabolites |
| MeSH PA | D057847 | Lipid Regulating Agents |
| FDA EPC | N0000175596 | Peroxisome Proliferator Receptor alpha Agonist |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:49103 | drug metabolite |
| CHEBI has role | CHEBI:83399 | marine xenobiotic metabolite |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35821 | anticholesteremic drug |
Related Drugs by ATC class:
C10AB Fibrates 11 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypercholesterolemia | indication | 13644009 | |
| Hyperlipidemia | indication | 55822004 | DOID:1168 |
| Hypoalphalipoproteinemia | indication | 190785000 | |
| Familial hypercholesterolemia - heterozygous | indication | 238079002 | |
| Mixed hyperlipidemia | indication | 267434003 | |
| Hypertriglyceridemia | indication | 302870006 | |
| Agranulocytosis | contraindication | 17182001 | DOID:12987 |
| Myositis | contraindication | 26889001 | DOID:633 |
| Primary biliary cirrhosis | contraindication | 31712002 | DOID:12236 |
| Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
| Hypothyroidism | contraindication | 40930008 | DOID:1459 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Chronic renal failure syndrome | contraindication | 90688005 | |
| Disorder of muscle | contraindication | 129565002 | DOID:423 |
| Liver function tests abnormal | contraindication | 166603001 | |
| Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
| Impaired renal function disorder | contraindication | 197663003 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Rhabdomyolysis | contraindication | 240131006 | |
| Calculus in biliary tract | contraindication | 266474003 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Thromboembolic disorder | contraindication | 371039008 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.71 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 105MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7569612 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS |
| 105MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7741373 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA |
| 105MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7741374 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS |
| 105MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7741374 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA |
| 105MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7915247 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS |
| 105MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7915247 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA |
| 105MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7915247 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA |
| 35MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7569612 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS |
| 35MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7741373 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA |
| 35MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7741374 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS |
| 35MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7741374 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA |
| 35MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7915247 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS |
| 35MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7915247 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA |
| 35MG | FIBRICOR | ROSEMONT | N022418 | Aug. 14, 2009 | DISCN | TABLET | ORAL | 7915247 | Aug. 20, 2027 | ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor alpha | Nuclear hormone receptor | AGONIST | Ki | 4.46 | CHEMBL | CHEMBL | |||
| Fatty acid-binding protein, intestinal | Cytosolic other | Ki | 6 | CHEMBL | |||||
| Solute carrier family 22 member 12 | Transporter | IC50 | 4.96 | CHEMBL | |||||
| Fatty acid-binding protein, liver | Cytosolic other | Kd | 7.03 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4BMH7IZT98 | UNII |
| D08890 | KEGG_DRUG |
| 4028374 | VANDF |
| C2586675 | UMLSCUI |
| CHEBI:749591 | CHEBI |
| CHEMBL1201745 | ChEMBL_ID |
| 11350701 | PUBCHEM_CID |
| CHEMBL981 | ChEMBL_ID |
| 8868 | INN_ID |
| C006012 | MESH_SUPPLEMENTAL_RECORD_UI |
| C014892 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB13873 | DRUGBANK_ID |
| 1433887 | RXNORM |
| 167897 | MMSL |
| 26077 | MMSL |
| d07371 | MMSL |
| 012921 | NDDF |
| 012922 | NDDF |
| 374531000221105 | SNOMEDCT_US |
| 442749005 | SNOMEDCT_US |
| 442750005 | SNOMEDCT_US |
| F5A | PDB_CHEM_ID |
| 2662 | IUPHAR_LIGAND_ID |
| 856676-23-8 | SECONDARY_CAS_RN |
| 4BMH7IZT98 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Fenofibric Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1324 | CAPSULE, DELAYED RELEASE | 45 mg | ORAL | ANDA | 25 sections |
| Fenofibric Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1325 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | ANDA | 25 sections |
| Fenofibric Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1554 | CAPSULE, DELAYED RELEASE | 45 mg | ORAL | NDA authorized generic | 30 sections |
| Fenofibric Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1555 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | NDA authorized generic | 30 sections |
| FIBRICOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13310-101 | TABLET | 35 mg | ORAL | NDA | 27 sections |
| FIBRICOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13310-102 | TABLET | 105 mg | ORAL | NDA | 27 sections |
| Fenofibric acid | Human Prescription Drug Label | 1 | 33342-294 | CAPSULE, DELAYED RELEASE | 45 mg | ORAL | ANDA | 26 sections |
| Fenofibric acid | Human Prescription Drug Label | 1 | 33342-295 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | ANDA | 26 sections |
| FENOFIBRIC ACID DELAYED-RELEASE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42385-944 | CAPSULE, DELAYED RELEASE | 45 mg | ORAL | ANDA | 18 sections |
| FENOFIBRIC ACID DELAYED-RELEASE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42385-945 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | ANDA | 18 sections |
| Fenofibric acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-347 | CAPSULE, DELAYED RELEASE | 45 mg | ORAL | ANDA | 26 sections |
| Fenofibric acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-348 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | ANDA | 26 sections |
| Fenofibric Acid | Human Prescription Drug Label | 1 | 46708-244 | CAPSULE, DELAYED RELEASE | 45 mg | ORAL | ANDA | 26 sections |
| Fenofibric Acid | Human Prescription Drug Label | 1 | 46708-245 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | ANDA | 26 sections |
| Fenofibric acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4373 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | ANDA | 27 sections |
| Fenofibric Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4561 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | NDA authorized generic | 27 sections |
| Trilipix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5986 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | NDA | 26 sections |
| FENOFIBRIC ACID | Human Prescription Drug Label | 1 | 59651-216 | CAPSULE, DELAYED RELEASE | 45 mg | ORAL | ANDA | 26 sections |
| FENOFIBRIC ACID | Human Prescription Drug Label | 1 | 59651-217 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | ANDA | 26 sections |
| Fenofibric Acid | Human Prescription Drug Label | 1 | 62332-244 | CAPSULE, DELAYED RELEASE | 45 mg | ORAL | ANDA | 26 sections |
| Fenofibric Acid | Human Prescription Drug Label | 1 | 62332-245 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | ANDA | 26 sections |
| Fenofibric Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68134-601 | TABLET | 35 mg | ORAL | NDA authorized generic | 26 sections |
| Fenofibric Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68134-602 | TABLET | 105 mg | ORAL | NDA authorized generic | 26 sections |
| Fenofibric acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-128 | CAPSULE, DELAYED RELEASE | 45 mg | ORAL | ANDA | 25 sections |
| Fenofibric acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-129 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | ANDA | 25 sections |
| FENOFIBRIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69315-281 | CAPSULE, DELAYED RELEASE | 45 mg | ORAL | ANDA | 18 sections |
| FENOFIBRIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69315-281 | CAPSULE, DELAYED RELEASE | 45 mg | ORAL | ANDA | 18 sections |
| FENOFIBRIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69315-282 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | ANDA | 18 sections |
| FENOFIBRIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69315-282 | CAPSULE, DELAYED RELEASE | 135 mg | ORAL | ANDA | 18 sections |
| FIBRICOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69916-035 | TABLET | 35 mg | ORAL | NDA | 27 sections |